Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/dmcn.16101 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Specific symptomatology profile associated with treatment resistant depression: A multicentric study from the Group for the Study of Resistant Depression with a focus on sex.
J Affect Disord
January 2025
Department of Medicine and Surgery, Kore University of Enna, Italy; Oasi Research Institute-IRCCS, Troina, Italy. Electronic address:
Background: Clinical predictors of treatment-resistant depression could improve treatment strategies. Depressive symptom profiles at baseline are potential outcome predictors, but little evidence is available, and sex-specific profiles have been scarcely investigated.
Methods: Baseline symptom scores of 1294 patients with major depressive disorder were assessed by the Montgomery-Åsberg depression rating scale (MADRS) as part of a multicenter study by the "Group for the Studies of Resistant Depression".
Retrospective analysis of amantadine response and predictive factors in intensive care unit patients with non-traumatic disorders of consciousness.
Front Neurol
January 2025
Department of Neurology & Stroke, University Hospital Tübingen, Tübingen, Germany.
Background: Disorders of consciousness (DoC) in non-traumatic ICU-patients are often treated with amantadine, although evidence supporting its efficacy is limited.
Methods: This retrospective study analyzed non-traumatic DoC-patients treated with amantadine between January 2016 and June 2021. Data on patient demographics, clinical characteristics, treatment specifications, and outcomes were extracted from electronic medical records.
Assessing early therapeutic drug monitoring of adalimumab as a predictor of treatment efficacy and immunogenicity in rheumatic diseases: "early therapeutic drug monitoring of adalimumab".
Clin Rheumatol
January 2025
Department of Public Health, University of Murcia, Campus de Ciencias de la Salud, Murcia, 30120, Spain.
Introduction: Therapeutic drug monitoring (TDM) in inflammatory rheumatic diseases (RMDs) is gaining interest. However, there are unresolved questions about the best practices for implementing TDM effectively in clinical settings.
Objective: The primary objective of this study was to evaluate whether early TDM of adalimumab predicts drug survival at 52 weeks in patients with RMDs.
[Development of a predictive scoring model for non-response to intravenous immunoglobulin in Kawasaki disease].
Zhongguo Dang Dai Er Ke Za Zhi
January 2025
Department of Pediatrics, Sichuan Provincial Women's and Children's Hospital/Affiliated Women's and Children's Hospital of Chengdu Medical College, Chengdu 610045, China.
Objectives: To explore the predictive factors for non-response to intravenous immunoglobulin (IVIG) in children with Kawasaki disease (KD) and to establish an IVIG non-response prediction scoring model for the Sichuan region.
Methods: A retrospective study was conducted by collecting clinical data from children with KD admitted to four tertiary hospitals in Sichuan Province between 2019 and 2023. Among them, 940 children responded to IVIG, while 74 children did not respond.
Oral Microbiota Associated with Clinical Efficacy of Ustekinumab in Crohn's Disease.
Endocr Metab Immune Disord Drug Targets
January 2025
Department of Stomatology, The Affiliated Huaian No.1 People's Hospital, Nanjing Medical University, No.1 Huanghe West Road, Huaian, 223300, Jiangsu Province, China.
Background: Crohn's Disease (CD) is a chronic inflammatory gastrointestinal disease. Ustekinumab (UST) has been utilized as a therapeutic option for CD patients. However, approximately 40-60% of patients exhibit an inadequate response to UST.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!